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Background: Estimates of prevalence are known to be affected by the design of cross-sectional studies. A
pan-European study provided an opportunity to compare the effect of two cross-sectional study designs on
estimates of medicines use.
Methods: A Service evaluation survey (SES) and a web-based point-prevalence study (PPS) were conducted as part
of a European study of neonatal exposure to excipients. Neonatal units from all European Union countries plus
Iceland, Norway, Switzerland and Serbia were invited to participate. All medicines prescribed to neonates were
recorded during three-day and one-day study periods in the SES and PPS, respectively. In the PPS individual
demographic and prescription data were also collected.
To compare the probabilities that a particular medicine would be reported by each study multilevel mixed effects
logistic regression models with crossed random effects were applied. The relationship between medicines exposure
at the unit and individual levels in the PPS data was assessed using polynomial regression with square root
transformation.
Results: Of 31 invited countries 20 and 21 with 115 and 89 units joined the SES and PPS, respectively. Out of
5,572,859 live births in invited countries in 2010 a higher proportion was covered by units participating in the SES
compared to the PPS (11% vs 6%, respectively; OR 1.89; 95% CI 1.87-1.89). A greater number of active
pharmaceutical ingredients (API), manufacturers and trade names were registered in the SES compared to the PPS.
High correlation between the two studies in frequency of use for each specified API was seen (R2 = 0.86). The
average probability of a department to use a given API was greater in the SES compared to the PPS (OR 2.36; 95%
CI 2.05-2.73) with higher frequency of use and longer average duration of prescription further increasing the
difference. The polynomial regression model described the correlation between APIs exposure on unit and
individual level well (R2 = 0.93).
Conclusion: The simple data structure and longer study period of the SES resulted in improved recruitment and
higher likelihood of capture for a given API. The frequency of use at the unit level appears a good surrogate of
individual exposure rates.
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Newborn babies receive a range of medicines many of
which have not been studied adequately. Furthermore,
exposure to medicines introduces risks and risk assess-
ment requires information about the extent of medicines
use. One neglected source of risk is the inclusion of ex-
cipients in medicines. Thus there is a need to gather in-
formation about medicines use in a way that captures
data about active pharmaceutical ingredients (API) and
the excipients. Variability in excipient content between
formulations of the same API needs to be considered.
Cross-sectional studies are attractive for studies of
medicines use [1-7]. In principle, data can be collected
at unit or individual level. Unit level data involve listing
all the products used on a unit over a specified period of
time. These data are simple to collect and can be inte-
grated with processes for medicines supply (such as sales
or dispensing activity). Unit level data indicate which
medicines are used (including how many distinct prod-
ucts, APIs and excipients are used) and will indicate
whether there are geographical differences in medicines
use. In combination with demographic data about the
units this method can provide indicative estimates of
market size. Individual level data require an extra step of
data collection. This approach captures denominator
data and generates more precise estimates of market size
while allowing for stratification according to important
clinical variables such as age of the baby. Point prevalence
studies (PPS) have been used in antibiotic consumption
studies [4,5,8]. Their extremely short duration may under-
estimate exposure to less frequently used medicines. Unit
level studies can have a longer duration but may not be
manageable in a multinational setting [9]. Although a re-
cent analysis has described the impact of cross-sectional
study designs on disease incidence/prevalence estimates
[10], little is known about the effects of study design in
research about medicines use. We are not aware of any
head to head comparison of different methods and thus
the question how to navigate between different methods
in medicine exposure research remains unanswered.
Within the European Study of Neonatal Excipient
Exposure (ESNEE) we planned to use both unit and in-
dividual level data collection in order to maximise yield
for two different study questions. [11]. This gave us the
opportunity to compare the two study designs – a short
duration PPS and longer lasting service evaluation survey
(SES). We used APIs as the unit of analysis in this meth-
odological study.
Accordingly, we aimed (1) to describe the implementa-
tion of each method; (2) to assess the extent of discord-
ance between the methods by comparing the probabilities
that particular medicines would be reported by each
method; (3) to explore the correlations between medi-
cines exposure at unit and individual levels.Methods
The SES and PPS were performed as multicentre observa-
tional surveys of routine clinical practice. During the SES
all medicines prescribed to neonates (≤28 days of postna-
tal age) were recorded on pre-formulated Excel spread-
sheets over three consecutive days within a fixed period of
time from May 30th to September 30th, 2011. PPS data
collection was performed in a web-based database within
one day during one of three fixed two-week study periods
from January to February; March or May to June, 2012.
Each participating unit was free to choose the most appro-
priate day(s) for data collection. In both surveys printable
data collection forms were provided as an alternative to
electronic data insertion.
Participating units and study population
The study aimed to cover all 27 European Union countries
plus Iceland, Norway, Switzerland and Serbia. A network
of national contact persons (Lead Contacts) was built by
the ESNEE consortium. Search for national Lead Contacts
was carried out through national professional/scientific so-
cieties of neonatology, paediatrics and/or perinatology as
well as through personal contacts of the ESNEE consor-
tium members or other FP-7-funded consortia (NeoMero,
TINN) [12,13]. The Lead Contact was then asked to re-
cruit as many hospitals and units providing neonatal
care in the country as possible.
At the outset, a PPS sample size estimation was planned.
It was intended to base this on cluster sampling analysis
stratified by country, assuming conservatively a 15%
neonatal admission rate of all live births [14-17] and a
response rate of 50-70% of invited units as described in
previous neonatal surveys [18-21]. Based on the Eurostat
NUTS (or equivalent if NUTS classification not available
for the country) regional distribution of the population
and reported nation-wide birth rates, the number of po-
tentially available neonatal admissions would be calculated
and the representative sample size estimated for each
country and region [22]. A complete list of institutions
involved in neonatal care would be created for each
randomly chosen NUTS2 region with subsequent in-
volvement of all units to cover a whole region with
proportional representation of different unit levels. Al-
ternatively, if a full list of neonatal units was not avail-
able and/or the response rate in the SES would suggest
critically low recruitment, all contacts provided by
Lead Contacts were to be invited to participate in the
PPS.
All general neonatal, intermediate and neonatal inten-
sive care (NICU) as well as mixed paediatric and neonatal
intensive care units with more than 50% of admissions
consisting of neonates were eligible with stratification ac-
cording to the level of care: level 1 with special neonatal
care; level 2 with high dependency care, short term
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with comprehensive intensive care for extremely low
birth weight infants available [23,24]. Departments, of-
fering different levels of care were classified according
to the highest level they provided.
Data collection
In both studies all eligible neonates in the unit at 8 a.m.
of the study day and in the SES additionally those admit-
ted within the next 72 h, were included. The SES recorded
the number of neonates receiving any prescription during
the study period. In the PPS individual demographic data
including gender, gestational age (GA), birth weight, 1st
and 5th minute Apgar score, current body weight, post-
natal age and organ dysfunctions, were recorded for all
neonates receiving any prescriptions active on the study
morning at 8 a.m.
Prescription data
All prescriptions, including micronutrients, iron, vitamins,
parenteral nutrition solutions and topical agents were re-
corded. Blood products, glucose and electrolyte solutions,
vaccines, nursery care topical agents, herbal medicines
and food including breast milk fortifiers were excluded.
The following information was collected for every medi-
cine prescribed: trade name, manufacturer, API, strength,
pharmaceutical dosage form and route of administration.
Additionally individual dosing regimen together with pre-
scription starting date was collected in the PPS.
Extemporaneous or compounded forms of medicines
were not included in described analysis. The use of caf-
feine and morphine was reported differently in the two
studies. UK units using ´special´ manufactured [25] prepa-
rations, rather than extemporaneous formulations used in
the rest of European countries, were over-represented in
the PPS. Accordingly, these two APIs were excluded from
the analysis.
In both studies the data were pooled for analysis without
any comment on treatment strategies of individual par-
ticipating units.
Data management and statistical analysis
SES data collection forms were checked for legibility
with two rounds of queries regarding missing data (re-
sponse rate 52%). Each medication was classified accord-
ing to brand name, manufacturer and pharmaceutical
dosage form. The list of medicines obtained in the SES
was used to prepopulate choices in the PPS database. To
minimize the risk of data entry errors all ´newly appear-
ing´ medicines in the PPS were added to the database by
the ESNEE team.
Statistical analysis was performed with Stata Software
(ver. 12.1). Descriptive statistics were used as appropriateto describe the variability of medicine exposure in both
studies.
To identify the effect size of the study method, the
average probabilities of the units to use any given API in
SES vs PPS were compared by multilevel mixed effects
logistic regression models with crossed random effects
[26]. Since the sample of departments in the two studies
was partly overlapping, department and API were added
to the model as a random effect when comparing the
average odds of using an API between the two study
methods. The outcome variable was a binary indicator
showing whether an API was used in a specific unit in a
specific study. The analysis was limited to agents used in
more than one unit in the SES. All models were adjusted
for geographic region (Northern, Southern, Western and
Eastern Europe according to the United Nations Statistics
department [27]) and unit level. These variables were
identified as potential confounders in an exploratory
population averaged Poisson regression model with ro-
bust standard errors [28] analysis including 10 most
often used APIs. Furthermore the effect of unit size (de-
scribed by number of annual admissions), frequency of
a given medicine use (described by proportion of units
using it) and the duration of the prescription (described
by the average time from the start of prescription to the
PPS study day) on the estimated method effect size was
explored.
To study the relationship between the number of
units using each API and the number of prescriptions
for that API polynomial regression model with square
root transformation was used based on the PPS data.
Ethical considerations
The SES did not collect any personal data and so did
not require ethics committee approval in any of the par-
ticipating countries. For participation in the PPS Ethics
Committee approval was obtained in compliance with the
respective national guidelines. In compliance with local
authorities no consent for individual patients was sought,
as all data were collected in routine clinical practice and
anonymised before leaving study sites.
Results
Characterisation of participating units
The cluster randomised approach to sample size calcula-
tion described in Methods section, was not feasible be-
cause no country had a full list of neonatal units.
Accordingly, all country Lead Contacts were invited to
participate in the PPS with as many units as possible. Of
31 invited countries 20 and 21 (Austria, Belgium, Bulgaria,
England, Estonia, Greece, Hungary, Ireland, Italy, Latvia,
Lithuania, Norway, Portugal, Romania, Serbia, Slovenia,
Spain and Switzerland in both; Denmark and Poland only
in the SES; Malta, France and the Netherlands only in the
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PPS, respectively. The number of units per country varied
from one to 20. In the SES compared to the PPS a higher
proportion of annual live births was covered overall (11%
vs 6% of 5,572,859 live births in participating countries in
2010, respectively; OR 1.89; 95% CI 1.87-1.89) and in each
European region (Table 1). Regional distribution varied
with higher representation of Eastern compared to
Western Europe (10% and 6% of 968,910 and 1,987,904
live births, respectively; OR 1.80; 95% CI 1.78-1.81) and
lower compared to Northern and Southern European
countries (12% and 18% of 1,357,998 and 1,258,047; OR
0.52; 95% CI 0.51-0.52 and 0.84; 0.83-0.84, respectively)
in the SES. The same regional distribution was seen in the
PPS (data not shown). No difference in the prevalence ofTable 1 Characteristics of participating units in the SES
and the PPS
SES PPS OR (95% CI)
No of participating countries 20 21 NA
No of participating hospitals 102 73 NA
No of participating units 115 89 NA
Median (IQR) No of
participating units per country
3.5 (1.75;7.75) 3 (2;5) NA
No (%) of teaching hospitals 62 (61%) 56 (77%) 0.47 (0.24-0.92)
Level distribution (%)
Level 3 60 73 0.56 (0.31-1.03)
Level 2 33 21 1.84 (0.97-3.50)
Level 1 6 6 1.13 (0.35-3.69)
Total annual live births in
catchment area of participating
units* (year of reference: 2010)
593,001 349,465 1.89 (1.87-1.89)
Regional proportions of live
births covered (%)**
Eastern Europe 10 4 2.79 (2.75-2.82)
Northern Europe 18 8 2.55 (2.53-2.57)
Southern Europe 12 9 1.30 (1.27-1.31)







3.95 (2.74) 2.59 (1.48) 1.58 (1.48-1.68)
No of neonates in unit in the
study period
3080‡ 1382 NA
No of neonates receiving any
drug prescription during the
study period
2050 825 1.34 (1.18-1.53)
*Data available for 107 units in the SES and for 48 hospitals in the PPS;
**calculation of proportions was based on the total number of live births in
given region in 2010 (source of data: Eurostat; last update: 03.04.2013); α data
available for 104 units in the SES and for 82 units in the PPS; ¥ based on data
from 102 units in the SES and 82 units in the PPS where both annual number
of admissions and number of patients during survey were available; ‡ data
available for 107 units.different levels of care between the two studies was ob-
served. However, the prevalence of teaching hospitals was
lower in the SES as compared to the PPS (OR 0.47; 95%
CI 0.24-0.92) (Table 1). Similarly, the proportion of all an-
nual admissions in units covered by the study was higher
in the SES than the PPS (3% and 2% of 90235 and 61392
admissions, respectively; OR 1.58; 95% CI 1.48-1.68).
Consumption of medicines in the PPS and the SES
More neonates in the SES received at least one drug
prescription compared to the PPS (OR 1.34; 95% CI
1.18-1.53) (Table 1). In total, a greater numbers of APIs,
manufacturers and trade names were registered during
the SES than the PPS (Table 2). Slightly lower preva-
lence of enteral and higher prevalence of topical formu-
lations was noted in the SES compared to the PPS with
no difference in parenteral medicines use. In the PPS the
number of prescriptions per neonate was inversely related
to GA the average (SD) count per neonate being 4.53
(2.33); 3.95 (2.59); 2.68 (1.91) and 2.31 (1.93) in the GA
bands of <28; 28–31; 32–36 and >36 weeks, respectively.
Correlation of medicine use between SES and PPS
Altogether 99 APIs were used in more than one unit in
the SES and were included into further analysis. As shown
in Figure 1 almost all APIs were more frequently used
in the SES compared to the PPS but the 95% CIs were
overlapping for the majority.
In multilevel mixed effects logistic regression models
with crossed random effects the average probability of
the departments to use each of the most common API
was higher in the SES compared to the PPS (OR 2.36; 95%
CI 2.05-2.73; p < 0.0005). The frequency of use and aver-
age duration of prescription further increased the likeli-
hood of being registered in favor of the SES by 1.01 times
(95% CI 1.01-1.02; p < 0.0005) and 1.02 times (95% CITable 2 Medicines consumption in the SES and the PPS
SES PPS OR (95% CI)
No of prescriptions during the study
period
NA 2608 NA
Median (IQR) No of prescriptions per
neonate
NA 2 (1;4) NA
No of active ingredients prescribed* 313 280 NA




No of manufacturers 332 235 NA
Route of administration (%)
Parenteral 58 59 0.96 (0.79-1.17)
Enteral 30 36 0.79 (0.64-0.97)
Topical 12 5 2.32 (1.57-3.42)































Figure 1 Proportions of units prescribing frequently used active substances in the SES and the PPS. The SES and PPS data presented as
triangles and circles, respectively. Active substances that were used in more than one unit in the SES (n = 99) are presented. Each number on the
x-axis identifies the individual active substance. Upper 95% CI in the SES and lower 95% CI in the PPS are shown in error bars.
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quency and day in duration of prescription, respectively.
Size of the department did not influence the capture
probability (OR 0.99; 95% CI 0.99-1.00; p = 0.652).
As shown in Figure 2 a high correlation in the fre-
quency of medicine use between the SES and the PPS
was observed (R2 = 0.86).
We next evaluated the correlation between the num-
ber of prescriptions per given API and the number of
units using that API in the PPS. As shown on Figure 3
there was a high correlation between these two variables
in polynomial regression model with square root trans-




































Figure 2 Correlation in the frequency of medicine use between the S
PPS for active substances used in more than 1 unit in the SES is shown. TreDiscussion
By applying two different study designs in comparable
target populations we have demonstrated that simple
data structure and longer study period used in the SES
improved recruitment and the likelihood of capture of
medicines consumption. The probability of capture for
a given API was further enhanced by higher frequency
of use and longer duration of prescription. This meant
that the SES gave a more comprehensive list of trade
names, APIs and manufacturers than the PPS. The list
of most frequently used APIs was overlapping in 90%
with high correlation of use frequencies between the
two studies.40% 50% 60% 70% 80%
s using a drug in SES
ES and the PPS on unit level. Correlation between the SES and the


























Number of using departments
Figure 3 Correlation between medicines exposure at unit and individual levels. Number of units using each specified active ingredient
(n = 99) in relation to the number of prescriptions in the PPS was observed. Polynomial regression trendline for active ingredients used in more
than one unit in the SES is shown. √number of prescriptions = 0.421 *(number of departments) – 0.004 *(number of departments)2 + 0.485;
R2 = 0.93.
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simplicity and uniformity of data collection. A two-step
approach, as used in the ESNEE project may allow sim-
ultaneous coverage of both unit-level and individual-
level data in neonatal excipient exposure studies, where
hardly any multi-country data are available. We have re-
cruited so far one of the largest international cohorts of
neonatal units from 21 European countries revealing a
surprisingly wide list of medicines. The number of trade
names applied in NICU setting was also high. The re-
sponse rate of 71% on country level as well as the num-
ber of prescriptions per neonate [9,29] are similar to
those reported previously [18-21]. Against the back-
ground of rising safety concerns of neonatal medicine/
excipient exposure, the wide trade name list from the
SES allows identification of substitution possibilities,
while individual exposure data from the PPS provide a
more precise quantification of the problem.
Different study designs can be applied in pharmacoe-
pidemiology [30,31]. Cohort studies have the advantage
of allowing data collection over prolonged time periods
which is more likely to capture rare exposures. However,
the expense and duration make it hard to implement co-
hort designs in multinational studies [9]. Case–control
studies allow rich data collection when a limited number
of medicines/excipients are targeted and data collection
is limited to a few centers. The PPS and SES, in contrast,
are easy to perform in multinational settings. They are
time and resource saving and to some extent cover each
other`s shortcomings like under- or overestimated expos-
ure rates of rarely used medicines or need for individual
data [30]. Alternately, nested study designs with longitu-
dinal data collection allow linkage between differentdatasets and may prove the best option. However, to the
best of our knowledge, it has hardly been used in paediat-
ric pharmacoepidemiological studies.
When planning medicine/excipient exposure studies
the research question to be answered needs to be balanced
against the implications of study design. We recognize
that a 3-day survey is actually very short in duration. How-
ever, even this small longitudinal component resulted in a
more comprehensive list of medicines due to the better re-
cruitment when simple data structure was used. On the
other hand, when individual exposures of frequently used
medicines are targeted, the increasing data volume (both
structure and duration) needs to be weighed against evolv-
ing decrease in compliance that may lead to underestima-
tion of prevalence [32]. It has been shown that the longer
the recall period, the greater the imprecision (especially
underestimation) of prevalence estimates [33,34], although
this finding may be more relevant in non-medical infor-
mants [10]. Furthermore, not only optimal recruitment
but also sample size maintenance over the course of a
study becomes an issue [35].
Additionally, economic evaluation plays a role in the
choice of a specific study design. There is considerable
overlap between acceptable methodologies and those
sanctioned by health economists [36]. Although phar-
macoeconomic analysis remains beyond the scope of
this study, a few comments can be made. There were no
major cost-differences in conducting these studies with
the exception of those associated with the development
of the PPS database. Web-based collection with auto-
mated control of data completeness was applied to im-
prove compliance and quality of reporting. We believe
that wherever sufficient to answer the research question,
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allocation. However, when a more complex format is
required, reasonable additional expenditure on data
collection tools may result in an improved cost-benefit
ratio.
We have also shown a high correlation between APIs
exposure on unit and individual level. This should allow
an indirect individual exposure assessment from less de-
manding approach like SES under the condition of limited
resources. We realize, that the estimates in the frequency
of medicine use in the PPS are systematically lower com-
pared to the SES. However, knowing the relationship be-
tween the two an estimate for one can be extrapolated
from the other. Nevertheless, such calculations should be
applied with caution and to estimate the exposure only for
the studied population as a whole. In neonatal studies
stratification by GA age allows a more meaningful risk
assessment due to the strong dependence of the maturity
of metabolic pathways on the postmenstrual age of the
newborn [37,38]. It has been shown previously and also by
us that medicines utilization pattern in extreme prematur-
ity is different from that near or at term [9,29,39,40].
Therefore, the PPS approach should be preferred to obtain
individual exposure estimates in neonates of different GA.
Some limitations of the present study need to be noted.
First, the quality of data collection was dependent on the
personnel entering the data. In both studies data insertion
was done by medical specialists according to standardized
protocols. As for the quality of reported data, in the SES
most queries concerned demographic data; only a few
queries were related to the information about medicines.
Second, neonatal units were given the option of selecting
the most appropriate day(s) for data collection. This could
lead to underestimation of medicine use because less busy
day(s) probably were more likely to be chosen. However,
we believe that eventually this approach captured informa-
tion on a larger number of neonates and medicines
through improved compliance and a larger number of par-
ticipating units. Third, the slightly different representation
by country required exclusion of two APIs from final ana-
lyses due to differences in regional handling/approach.
Fourth, the SES and the PPS were done at different times.
Nested design with detailed individual data collection
(PPS) performed as part of the SES was not feasible, as an
interim between the two studies was needed to prepopu-
late the PPS database from the SES list of medicines. This
could potentially reduce the overlap between the studies.
In that situation our data about overlap represent a “worst
case scenario”. The true concordance in API reporting
may be higher than described by us. Finally, about two
thirds of the 31 invited countries agreed to participate
with relative inhomogeneity of the regional distribution
of participating units. Although the inability to randomly
select hospitals probably caused overrepresentation ofteaching hospitals (61% and 77% in the SES and PPS, re-
spectively, compared to less than 10%, reported in na-
tional hospital statistics [41]), data on the distribution
of the levels of neonatal care will allow appropriate ad-
justments. Both SES and PPS have achieved representa-
tive sample size on patient level, the margin of error
being 1.73% and 2.63%, respectively (CI 95%; response
distribution 50%; population size 5.4 million live births).
However, it would be valid under the condition of ran-
domisation that remained unfeasible in our studies. Still,
the current analysis gives a notion of good coverage of the
target population in the SES and PPS.Conclusions
The less demanding approach of the SES allows better re-
cruitment of units for longer periods resulting in a more
comprehensive list of medicines and trade names. As we
have shown, the frequency of use on unit level appears a
good surrogate of individual exposure rates. However,
more detailed information can be collected in a PPS. In-
vestigators need to balance the advantages of a PPS with
the risk of bias, which depends on the frequency as well
as duration of medicine use. Simultaneous use of both
methods with merged data analysis will likely result in
optimal coverage of both aspects of the problem.Abbreviations
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